Blue test tubes arranged in a line, disappearing into the background

News

MHLW (Japan) approves Darvias injection to treat peripheral T cell lymphoma.-Solasia Pharma and Nippon Kayaku.

Read time: 1 mins

Published: 26th Jun 2022

Solasia Pharma K.K officially announced that an organoarsenic drug “Darvias Injection 135mg” (SP-02, hereinafter Darvias) has been approved for relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare (MHLW). Solasia filed an NDA with the MHLW in Japan in June 2021.

In October 2021, Nippon Kayaku Co., Ltd. (TSE: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) secured a license agreement with Darvias for marketing rights in Japan.

Condition: T- cell Lymphoma

Type: drug

Learning Zone

Advances in Lymphoma

Information on current lymphoma care and treatments for classic Hodgkin lymphoma (cHL), PTCL subtypes, relapsed DLBCL, and B-NHL.

Learning Zone

Supportive Care in Oncology Learning Zone

Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.

How do you prefer to access medical updates and information?

Listen to a podcast

Watch a video

Read an article

Other

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Moderna reports H5 Flu data

Moderna’s H5 flu vaccine shows strong immune response in Phase 1/2; HHS ends late-stage funding, new paths explored.

Drug news

Cibotercept in PAH ends

Published: 30th May 2025

Drug news

Khindivi cleared for pediatrics

Published: 30th May 2025

See all news